论文部分内容阅读
作者在慢性尿毒症患者中比较了巴斯德研究所生产的含有S和前S2抗原的重组乙型肝炎疫苗和血源性乙型肝炎疫苗的免疫原性。 选择120例HBsAg、抗-HBc和抗-HBs阴性血清转氨酶正常的慢性肾功能衰竭患者,随机分成两组,每组60人,在0、1、2、4和12个月（加强接种）分别肌肉接种20μg重组乙型肝炎疫苗（G组）或5μg血源性乙型肝炎疫苗（H组）接种后1、2、4、6、9、12和13个月采血标本,测定HBsAg、抗-HBc、抗-HBs和抗前S2抗体。 结果发现,在第3、4和加强接种后G组血清阳转率（抗-HBs效价≥2mIU/ml）分别是76％、85％和94％;N组分别是63％、67％和76％。G组抗-HBs几何平均滴度（GMT）分别为8.1、35.2和346.3;H组为9.9、27.2和133.4。G组血清保护水平（抗-HBs≥10mIU/ml）的百分率分别是44％、71％和84％,H组分别是46％、59％和70％,仅在加强注射后两组差异有显著性。加强接种后,两组抗-HBs GMT相似,G组为879mIU/ml,H组为1001mIU/ml。G组血清抗前S2抗体阳转率（30mIU/ml）和GMT皆高于H组,但仅在第3和第4次接种后有统计学差异。
The authors compared the immunogenicity of recombinant Hepatitis B and Hepatitis B vaccines containing the S and pre-S2 antigens produced by the Pasteur Institute in patients with chronic uremia. A total of 120 patients with chronic renal failure who had normal HBsAg, anti-HBc, and anti-HBs-negative serum aminotransferases were randomly assigned to two groups of 60 with 0, 1, 2, 4 and 12 months Blood samples were collected at 1, 2, 4, 6, 9, 12 and 13 months after inoculation of 20 μg of recombinant hepatitis B vaccine (group G) or 5 μg of blood-borne hepatitis B vaccine (group H) HBc, anti-HBs and anti-pre-S2 antibodies. The results showed that the seroconversion rates of G group (anti-HBs titer≥2mIU / ml) were 76%, 85% and 94% respectively after the third, fourth and fourth inoculation; the third group were 63%, 67% 76%. The geometric mean titers (GMTs) of anti-HBs in group G were 8.1, 35.2 and 346.3, respectively; those in group H were 9.9, 27.2 and 133.4. Serum levels of anti-HBs (anti-HBs ≥ 10 mIU / ml) were 44%, 71% and 84% in group G, 46%, 59% and 70% in group H, respectively Sex. After boosting, the anti-HBs GMTs were similar between the two groups, with 879 mIU / ml for G and 1001 mIU / ml for H. The serum anti-pre-S2 antibody positive rate (30mIU / ml) and GMT in group G were higher than those in group H, but there was statistical difference only after the third and fourth inoculation.